1. Yous S, Andrieux J, Howell HE, Morgan PJ, Renard P, Pfeiffer B, et al. Novel naphthalenic ligands with high affinity for the melatonin receptor. J Med Chem. 1992;35:1484–6.
2. Servier Laboratories Limited: Summary of product characteristics: Valdoxan 25 mg film-coated tablets [ http://www.medicines.org.uk/emc/medicine/21830/SPC/valdoxan/ ]
3. Therapeutic Goods Administration, Department of Health and Ageing: Australian public assessment report for agomelatine [ http://www.tga.gov.au/pdf/auspar/auspar-valdoxan.pdf ]
4. Taylor D, Sparshatt A, Varma S, Olofinjana O. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ. 2014;348:1–19. doi:10.1136/bmj.g1888.
5. Guaiana G, Gupta S, Chiodo D, Davies SJC, Haederle K, Koesters M. Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev. 2013;12(CD008851):1–135. doi:10.1002/14651858.CD008851.pub2.